Your exact protocol is reviewed with you before you start and adjusted with follow-up
There are exceptions, but for hair growth, oral peptide products generally do not produce the same clinical response as topical-plus-microneedling or injectable protocols
That is why a 150 mcg figure a fraction of what many injectable peptides use is the documented starting point for the 10 mg vial
Long-term safety and efficacy are unknown
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
